Gossamer Bio, Inc. (GOSS) – What Are Analysts Thinking About This Stock?

Gossamer Bio, Inc. (NASDAQ:GOSS) has been given a consensus rating of “Hold” by the ten analysts that are covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $256.00.

A number of equities analysts have recently commented on GOSS shares. Leerink Partners raised shares of Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 price objective for the company in a report on Tuesday, July 28th. HC Wainwright reissued a “buy” rating on shares of Gossamer Bio in a research note on Thursday, August 27th. Chardan Capital started coverage on shares of Gossamer Bio in a research note on Tuesday, October 13th. They issued a “buy” rating on the stock. Wall Street Zen lowered shares of Gossamer Bio from a “hold” rating to a “sell” rating in a research report on Sunday, September 20th. Finally, Weiss Ratings upgraded shares of Gossamer Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 9th.

Gossamer Bio Stock Up 2.2%

Shares of NASDAQ:GOSS opened at $9.79 on Thursday. The stock’s 50-day moving average is $11.62 and its 200-day moving average is $16.43. Gossamer Bio has a 52-week low of $8.29 and a 52-week high of $309.60.

Hedge Funds Weigh In On Gossamer Bio

Several institutional investors have recently bought and sold shares of GOSS. Corient Private Wealth LP grew its holdings in shares of Gossamer Bio by 41.3% during the second quarter. Corient Private Wealth LP now owns 5,632,698 shares of the company’s stock worth $927,000 after purchasing an additional 1,647,315 shares during the last quarter. Hsbc Holdings PLC increased its stake in shares of Gossamer Bio by 1,289.4% in the second quarter. Hsbc Holdings PLC now owns 1,583,118 shares of the company’s stock valued at $267,000 after buying an additional 1,469,175 shares in the last quarter. Bank of America Corp DE acquired a new stake in shares of Gossamer Bio in the second quarter valued at $65,000. Hhlr Advisors LTD. bought a new position in shares of Gossamer Bio in the second quarter valued at about $819,000. Finally, ARCH Venture Management LLC bought a new position in shares of Gossamer Bio in the second quarter valued at about $1,326,004. Institutional investors own 81.23% of the company’s stock.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with disorders involving the immune system, inflammation and fibrosis. The company is headquartered in San Diego, California, and primarily operates through the development of its proprietary drug candidates and strategic collaborations.

Gossamer’s lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways associated with pulmonary vascular remodeling.